...- FMS-like tyrosine kinase 3 (FLT3)-mutated disease documented in a local reference laboratory at the time of consideration for enrollment in the study...

...- Adults ≥18 years of age with acute myeloid leukemia (AML) and at least 1 prior line of therapy- FLT3-mutated disease documented in a local reference laboratory- Have the ability to understand the requirements and procedures of the study and sign a written informed consent form- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2- Adequate hepatic and renal function- Prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) ≤1.5x upper limit of normal (ULN) unless receiving therapeutic anticoagulation- Negative serum ß-human chorionic gonadotropin (HCG) test in women of child-bearing potential (WOCBP)- Left ventricular ejection fraction ≥50% confirmed by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan - Adultos ≥18 con leucemia mieloide aguda (LMA) y al menos una linea de tratamiento previa- Enfermedad con mutación en FLT3 documentada en laboratorio local de referencia- Capacidad para comprender los requisitos y procedimientos del estudio y firmar un consentimiento escrito- Puntuación de 0, 1 ó 2 en la escala ECOG- Función hepática y renal adecuada- Tiempo de protrombina, tiempo de activación parcial de tromboplastina y razón internacional normalizada (INR) ≤1.5x del límite normal superior a no ser que reciba anticoagulantes- HCG negativa en mujeres con capacidad de procrear- Fracción de eyección ventricular izquierda ≥50% confirmada por ecocardiograma o MUGA...

Differential analyses of data from flow cytometry (AML-HP-FC Cohort) and single cell imaging (AML-sc-MI Cohort) demonstrated: 1) sensitivity to ENTO and LANRA (³ 1uM) was higher in NPM1 and FLT3 mutated AML samples…